Innovative PK/PD approaches to improve dosing

9:30 AM • 3338 • Imipenem population pharmacokinetics in neutropenic adults patients > M. Matthieu LAFAURIE (Paris) 9:35 AM • 3863 • Model-informed translation of <em>in vitro</em> meropenem effects against <em>Pseudomonas aeruginosa</em> to diverse clinical situations > I. Iris K. MINICHMAYR (Uppsala) 9:40 AM • 387 • Characterisation of nacubactam pharmacokinetics-pharmacodynamics (PK-PD) for efficacy in combination with cefepime against carbapenemase-producing Enterobacterales in a one compartment<em> in vitro </em>infection model > B. Brian D. VANSCOY (Schenectady, Ny) 9:45 AM • 1412 • Population pharmacokinetic and the probability of target attainment of fosfomycin in healthy male volunteers > A. Angela Elma EDWINA (Rotterdam) 9:50 AM • 3607 • Population pharmacokinetics of cefazolin in maternal and umbilical cord sera and target attainment in term neonates > O. Omar ELKAYAL (Leuven) 9:55 AM • 3352 • Probability of target attainment of antibiotics in obese patients can conventional pharmacokinetic/pharmacodynamic targets adequately capture target-site penetration? > D. David BUSSE (Berlin) 10:00 AM • 1983 • Amikacin in emergency surgery: how to dose it optimally? > S. Sylvain GOUTELLE (Lyon) 10:05 AM • 981 • A semi-mechanistic model of the bactericidal activity of high-dose isoniazid against multidrug-resistant tuberculosis > K. Kamunkhwala GAUSI (Cape Town) 10:10 AM • 646 • Influence of the clindamycin-administration route on the magnitude of clindamycin-rifampicin interaction: a prospective pharmacokinetic study > V. Valérie ZELLER (Paris) 10:15 AM • INT5 • Q&A/Discussion